Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 27Lung Neoplasms 7Non Small Cell Lung Cancer Metastatic 3Neoplasm Metastasis 3Recurrence 2Advanced Non-Small Cell Lung Cancer 2ALK Positive Non-small Cell Lung Cancer 2Sexual Dysfunction, Physiological 1Non-Small Cell Lung Cancer ALK-positive 1Non Small Cell Lung Cancer ALK Positive or ROS1 Positive 1Neurofibromatosis 1 1Neoplasms 1Neoadjuvant Non-Small Cell Lung Cancer 1NSCLC 1Meningeal Carcinomatosis 1Lung Diseases 1Hyperlipidemias 1Hereditary Sensory and Autonomic Neuropathies 1Eunuchism 1Erectile Dysfunction 1Colorectal Neoplasms 1Brain Neoplasms 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Adenocarcinoma of Lung 1ALK-positive Non-small Cell Lung Cancer 1ALK-positive NSCLC 1

Interventions

Carboplatin 71Paclitaxel 49Radiotherapy 44Pemetrexed 42Cisplatin 41Bevacizumab 39Gemcitabine 27Docetaxel 27Erlotinib Hydrochloride 23Gefitinib 18pembrolizumab 14Taxes 13Vinorelbine 10Cetuximab 10Radiation 8Nivolumab 8Magnetic Resonance Spectroscopy 8capmatinib 7Radiosurgery 7Platinum 7Etoposide 7Surgical Procedures, Operative 6Radiotherapy, Conformal 6Mastectomy, Segmental 6ceritinib 5aflutinib 5Specimen Handling 5Neoadjuvant Therapy 5Cyclophosphamide 5Biopsy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × lorlatinib × Thoracic × Clear all
NCT06858410 2025-03-05

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Guangdong Association of Clinical Trials

Phase 3 Not yet recruiting
36 enrolled
Thoracic

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡